GF CART 03
Alternative Names: GF-CART03Latest Information Update: 15 Jan 2024
At a glance
- Originator Agency for Science, Technology and Research; GenomeFrontier
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 20 Oct 2023 GenomeFrontier and Agency for Science, Technology and Research agree to co-develop GF CART 03 for Solid tumours (GenomeFrontier pipeline, October 2023)
- 20 Oct 2023 GF CART 03 is available for licensing as of 20 Oct 2023. https://genomefrontier.com/partnership/
- 20 Oct 2023 GenomeFrontier receives notice of acceptance for patent application for Quantum pBac™ technology in New Zealand (GenomeFrontier pipeline, October 2023)